These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 26071430)

  • 41. A three-outcome design for phase II clinical trials.
    Sargent DJ; Chan V; Goldberg RM
    Control Clin Trials; 2001 Apr; 22(2):117-25. PubMed ID: 11306150
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Designing a series of decision-theoretic phase II trials in a small population.
    Hee SW; Stallard N
    Stat Med; 2012 Dec; 31(30):4337-51. PubMed ID: 22927289
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Curtailed two-stage designs with two dependent binary endpoints.
    Chen CM; Chi Y
    Pharm Stat; 2012; 11(1):57-62. PubMed ID: 22162348
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Bayesian dose-finding design for phase I/II clinical trials with nonignorable dropouts.
    Guo B; Yuan Y
    Stat Med; 2015 May; 34(10):1721-32. PubMed ID: 25626676
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Randomized two-stage Phase II clinical trial designs based on Barnard's exact test.
    Shan G; Ma C; Hutson AD; Wilding GE
    J Biopharm Stat; 2013; 23(5):1081-90. PubMed ID: 23957517
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bayesian dose selection design for a binary outcome using restricted response adaptive randomization.
    Meinzer C; Martin R; Suarez JI
    Trials; 2017 Sep; 18(1):420. PubMed ID: 28886745
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Continuous endpoints in Bayesian two-stage designs.
    Brutti P; De Santis F; Gubbiotti S; Sambucini V
    J Biopharm Stat; 2016; 26(5):966-77. PubMed ID: 26892274
    [TBL] [Abstract][Full Text] [Related]  

  • 48. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.
    Lin R; Yin G
    Stat Med; 2017 Nov; 36(26):4106-4120. PubMed ID: 28786138
    [TBL] [Abstract][Full Text] [Related]  

  • 49. General keynote: clinical trial design.
    Berry DA
    Gynecol Oncol; 2003 Jan; 88(1 Pt 2):S114-6; S122-3. PubMed ID: 12586099
    [No Abstract]   [Full Text] [Related]  

  • 50. Planning for an adaptive design: a case study in COPD.
    Jones B; Atkinson G; Ward J; Tan E; Kerbusch T
    Pharm Stat; 2006; 5(2):135-44. PubMed ID: 17080770
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase II clinical trials in oncology: strengths and limitations of two-stage designs.
    Schlesselman JJ; Reis IM
    Cancer Invest; 2006; 24(4):404-12. PubMed ID: 16777694
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Bayesian predictive two-stage design for phase II clinical trials.
    Sambucini V
    Stat Med; 2008 Apr; 27(8):1199-224. PubMed ID: 17763528
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Continuous toxicity monitoring in phase II trials in oncology.
    Ivanova A; Qaqish BF; Schell MJ
    Biometrics; 2005 Jun; 61(2):540-5. PubMed ID: 16011702
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of single-arm vs. randomized phase II clinical trials: a Bayesian approach.
    Sambucini V
    J Biopharm Stat; 2015; 25(3):474-89. PubMed ID: 24896838
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Decision theoretic designs for phase II clinical trials with multiple outcomes.
    Stallard N; Thall PF; Whitehead J
    Biometrics; 1999 Sep; 55(3):971-7. PubMed ID: 11315037
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase II clinical trials in oncology: are we hitting the target?
    Ang MK; Tan SB; Lim WT
    Expert Rev Anticancer Ther; 2010 Mar; 10(3):427-38. PubMed ID: 20214523
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Generalized optimal design for two-arm, randomized phase II clinical trials with endpoints from the exponential dispersion family.
    Jiang W; Mahnken JD; He J; Mayo MS
    Pharm Stat; 2016 Nov; 15(6):459-470. PubMed ID: 27511063
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A bivariate Bayesian dose-finding procedure applied to a seamless phase I/II trial in rheumatoid arthritis.
    Thygesen H; Dragalin V; Whitehead A; Whitehead J
    Pharm Stat; 2012; 11(6):476-84. PubMed ID: 23011957
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A behavioural Bayes approach to the determination of sample size for clinical trials considering efficacy and safety: imbalanced sample size in treatment groups.
    Kikuchi T; Gittins J
    Stat Methods Med Res; 2011 Aug; 20(4):389-400. PubMed ID: 20223784
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A two-stage Bayesian design with sample size reestimation and subgroup analysis for phase II binary response trials.
    Zhong W; Koopmeiners JS; Carlin BP
    Contemp Clin Trials; 2013 Nov; 36(2):587-96. PubMed ID: 23583925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.